MAP2 and pancreatic ductal adenocarcinoma: A study by Large et al., (2019) showed microtubule-associated protein 2 (MAP2) to be a potential biomarker for gemcitabine resistance in two cohorts of pancreatic ductal adenocarcinoma (PDAC) patients [295].